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Abstract: OBJECTIVE To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on re-
lapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). METHODS
Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary
outcome measure was change in relapse rate after starting rituximab (Poisson regression model). RE-
SULTS Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were
treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1)
months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%)
remained relapse-free after median 12.1 (6.3-24.9) months. In this ’relapsing group’, relapse rate declined
by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first
line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunother-
apies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX
therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to
<1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses. CONCLUSION
RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent
B-cell depletion. Prospective controlled studies are needed to validate these results.
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Introduction: Rituximab (RTX), a B-cell depleting monoclonal antibody, is effective in 
treating many autoimmune disorders, including multiple sclerosis and aquaporin-4 antibody 
positive neuromyelitis optica spectrum disorders (AQP4-IgG-positive NMOSD).  Its efficacy 
in a large cohort of patients with myelin oligodendrocyte glycoprotein antibody-associated 
disorder (MOGAD) has not been assessed. 
 
Methods: Centres around the world with expertise in treating MOGAD were invited to 
provide retrospective data on relapses and disability in all of their MOGAD patients treated 
with RTX. Data were collected on 132 patients from 29 centres in 13 countries.  
 
Results: Data on 121 patients were analysed; 103/121 (85.1%) were white and 30/121 
(24.8%) were children. Because relapse risk after initial attack is uncertain in MOGAD, we 
analysed patients in two groups: those treated with RTX after a single attack, and those 
treated after two or more attacks (established relapsing disorders). 20/121 (16.5%) were 
treated after a single attack, of whom 14/20 (70.0%) remained relapse-free at median follow-
up of 11.2 months. 6/20 relapsed after a median interval of 2.6 months. 101/121 (83.5%) 
were treated with RTX after two or more attacks, and a 37% (95%CI=19-52%, p<0.001) 
reduction in relapse rate was observed overall. In this group, RTX was used as a 1st line 
steroid-sparing immunotherapy in 47/101 (46.5%) and as a 2nd/3rd line therapy in in 54/101 
(53.5%), most commonly after mycophenolate mofetil or azathioprine. The reduction in 
relapse rate with 1st line RTX therapy was 63% (95%CI=35-79%, p=0.001), and for 2nd/3rd 
line therapy 26% (95%CI=2-44%, p=0.038). In the relapsing group the predicted relapse-free 
survival at 2 years on RTX was 55% for 1st line therapy, and 18% for 2nd /3rd line therapy. 
Circulating CD19+ B-cells were undetectable or suppressed to <1% of total lymphocyte 
population at the time of 45/57 (78.9%) relapses. Median EDSS scores improved, and visual 
acuities did not change on RTX, though these data were incomplete.    
 
Conclusion: RTX treatment reduced relapse rates in MOGAD. However a significant 
proportion of patients continued to relapse, particularly those refractory to other non-steroid 
immunotherapies. Many relapses occurred despite robust B-cell depletion.  The reduction in 
relapse rates in this study is lower than that reported in AQP4-IgG-positive NMOSD. Further 
studies are therefore needed to inform the management of MOGAD.  
 
Introduction 
Myelin oligodendrocyte glycoprotein (MOG) is expressed on the outermost surface of myelin 
in the central nervous system and is speculated to provide structural integrity to the myelin 
sheath. Autoantibodies of the immunoglobulin G1 subtype targeting full-length human MOG 
(MOG-IgG) have been recently identified in the sera of both children and adults with a CNS 
inflammatory disease that is distinct from multiple sclerosis (MS).1-3 MOG-IgG may be 
detected in patients presenting with optic neuritis (ON), transverse myelitis (TM), acute 
disseminated encephalomyelitis (ADEM), encephalitis (including those with seizures) and 
rhombencephalitis.4-6 30-80% of patients relapse after an initial attack,6-9 and some fulfil 
revised diagnostic criteria for aquaporin-4 antibody (AQP4-IgG)-negative neuromyelitis 
optica spectrum disorders (NMOSD).9,10   
 
Although MOG-IgG-associated disorder (MOGAD) may overall be less severe than AQP4-
IgG-positive NMOSD, a significant proportion of patients do experience relapses and may 
accrue significant disability; severe visual impairment occurred in 36% of one cohort.9 Long-
term immunomodulatory treatment may therefore be reasonable in relapsing patients, 
especially those with severe attacks. However, there is very limited data on natural history, 
prognostic markers and treatment responses in MOGAD to inform the optimal treatment 
strategy. Drugs and treatment algorithms have been adopted from those being used in 
NMOSD and ADEM, and include corticosteroids, intravenous immunoglobulin (IVIg), 
azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX).11-13 The few 
retrospective studies to date suggest a benefit of these immunotherapies, but the numbers of 
patients treated with individual medications are relatively small and these studies do not 
provide a robust comparison between therapies.7-9,14,15 
 
RTX is a chimeric monoclonal antibody directed against CD20, a B-cell surface marker. 
Following intravenous infusion, circulating B-cells are rapidly eliminated, often to 
undetectable levels, an effect that persists for 6-12 months on average. Further infusions can 
be given at fixed six-month intervals or timed according to B-cell/memory B-cell 
repopulation.  
 
Anti-CD20 B-cell depletion has proven effective in MS.16-19 Similarly, numerous, 
predominantly retrospective, observational studies in AQP4-IgG-positive NMOSD have 
consistently reported approximately 80% reductions in annualised relapse rates following 
initiation of RTX.20-29 Given its efficacy in similar neuroinflammatory disorders, it is hoped 
that RTX may also be effective in MOGAD, but its benefit is not yet defined.  
 
Aim 
To examine the efficacy of RTX in a large international cohort of patients with MOGAD 
 
Methods 
Two authors (DHW and AJ) identified 24 neurologists and paediatric neurologists around the 
world with an interest in antibody-mediated CNS inflammation, 17 of whom (70.8%) 
submitted demographic, relapse and disability data on all patients in their care meeting the 
study inclusion criteria (box 1). They also provided the total number of MOGAD patients 
under their care.  
 








We included patients on ‘fixed’ RTX regimens, as long as the dosing interval did not exceed 
6-months, and patients on variable dosing regimens, provided they had adhered to at least 
two-monthly monitoring of either CD19+ B-cells or CD19+/CD27+ memory B-cells in 
peripheral circulation. 
 
Relapses were based on the judgement of the investigators at each participating centre. In 
clinical practice, relapses are defined as a new or worsening symptomatic presentation, 
supported by a change in neurological examination, and confirmed by MRI as necessary. We 
asked investigators to provide CD19+ B-cell counts at the time of relapses if available. 
 
We analysed treatment effect in several ways: A Poisson regression model was fitted to the 
data, with a random effect by patient level, to compare the relapse rate before and after 
initiating RTX (onset attack is excluded from this model). We also calculated the change in 
median annualised relapse rate (ARR) after initiation of RTX, and used Kaplan-Meier 
survival curves to estimate relapse-free survival. ARR is defined as the total number of 
relapses (including the onset attack) divided by the number of years of disease. Two 
subgroup analyses were performed: A comparison of those with prior exposure to other non-
1. At least one clinical and MRI-confirmed event consistent with CNS 
inflammation. 
2. MOG-IgG positive by live or fixed cell-based assay incorporating an IgG-
specific secondary antibody (MOG-IgG ELISA was not included). 
3. AQP4-IgG negative by live or fixed cell-based assay. 
4. Treatment with RTX at any point. 
steroid maintenance immunotherapies versus treatment naïve patients; and a comparison of 
adult and paediatric patients.  
 
Results 
Data were obtained from 29 centres in 13 countries – Argentina, Austria, Brazil, France, 
Germany, Netherlands, India, Italy, Japan, Korea, Switzerland, United Kingdom and United 
States of America. The total number of MOGAD patients attending all study centres was 875. 
RTX was administered to 132/875 (15.1%). Data on 121 patients were analysed and included 
in the study. Eleven patients were excluded from the analysis due to incomplete data (6), 
inadequate treatment protocol (4) and diagnostic uncertainty (1). 
 
Demographics 
Data on 121 patients (71/121, 58.7% female) were analysed (table 1). Median (interquartile 
range, IQR) age at onset attack was 24.8 (13.1-39.6) years and median age at first RTX 
infusion was 29.7 (18.2-44.0) years. Race distribution was 103/121 (85.1%) White, 10/121 
(8.3%) Asian, 1/121 (0.8%) Black, and 7/121 (5.8%) mixed race. Paediatric patients, 
meaning those that started RTX before age 18 years, comprised 30/121 (24.7%). The most 
common MOGAD phenotypes in adults were relapsing ON (27/91, 29.7%) and relapsing ON 
with TM (25/91, 27.5%). The most common phenotype in children was ADEM/ADEM-like 
with relapses (13/30, 43.3%).  
 
Relapses and immunotherapy prior to rituximab 
For all patients, the median (range) disease duration prior to treatment with RTX was 19.1 
(1.1-370.7) months. RTX was started after an index attack in 20/121 (16.5%), and after at 
least two attacks in 101/121 (83.5%). The pre-treatment median (IQR) annualized relapse rate 
(ARR) was 1.82 (0.74-3.40) for the 101 relapsing patients. Approximately half of these 
patients (54/101, 53.5%) were treated with one or more non-steroid immunotherapies before 
RTX (table 1). These included AZA in 26/101 (25.7%), MMF in 20/101 (19.8%) and IVIg in 
7/101 (6.9%). Other immunosuppressive drugs had been used in 13/101 (12.8%), and MS 
disease-modifying therapies (MS-DMTs) in 11/101 (10.9%). There was no standardised 
‘wash-out’ period of prior immunotherapies before starting RTX.  
 
Rituximab dosing 
RTX was administered as a fixed dosing regimen to 115/121 (95.0%) with an interval of 6 
months or less between treatment courses. If only a single treatment course was given, 
treatment duration was considered as 6 months. A variable dosing interval was used in 6/121 
(5.0%) on the basis of CD19+ B-cell count or CD19+/CD27+ memory B-cell counts. The most 
commonly prescribed RTX dose was 1000mg (79/121, 65.3%). For each treatment course, 
this was either infused once on day 0, or twice on day 0 and day 15. A body surface area 
adjusted dose of 375mg/m2, administered weekly for four weeks, was given to 28/121 
(23.1%) and was the usual dose for paediatric patients. A minority of patients received a mix 
of both dosing regimens (4/121, 3.3%), and in some cases exact dosing was not specified 
(10/121, 8.3%).  
 
The effect of RTX started after index attack (n=20) 
RTX was started after the index attack in 20/121 (16.5%). Because MOGAD may be 
monophasic in approximately half of cases (i.e. a significant proportion of these patients may 
never relapse irrespective of treatment), we analysed this group separately from those with an 
established relapsing phenotype prior to starting RTX. After a median (IQR) duration on 
RTX of 11.2 (6.3-14.1) months, 14/20 (70%) remained relapse-free. 11 relapses occurred in 
6/20 (30.0%) patients, with a median time to first relapse of 2.6 (1.3-4.5) months.  
 
The effect of RTX started after two or more attacks (n=101) 
RTX was started after two or more attacks in 101/121 (83.5%). The median pre-treatment 
duration (time from index attack to RTX initiation) was 26.0 (9.8-70.9) months.  The median 
observation period on RTX was 12.1 (6.3-24.9) months, during which 102 relapses occurred 
in 48/101 (47.5%) patients (figure 2). The median time to first relapse was 4.4 (1.8-8.5) 
months. Fitting a Poisson regression model showed a 37% (95%CI 19-52%, p<0.001) 
reduction in relapse rate following treatment with RTX. The Kaplan-Meier estimate of 
relapse-free survival was 55% (95%CI 44-65%) at 1 year of RTX therapy and 33% (95%CI 
20-46%) at 2 years (figure 3a).  
 
The effect of RTX on median ARR is shown in table 2. For all patients (n=101), the median 
ARR declined after initiation of RTX from 1.82 to 0.00 (p<0.001; Wilcoxon signed rank 
test). Because the calculation of ARR is dependent on the pre- and post-treatment observation 
periods, we repeated the analysis after excluding patients with short observation periods. In 
patients with at least 12 months pre-treatment observation (71/101, 70.3%), median ARR 
declined after initiation of RTX from 1.09 to 0.00 (p<0.001; Wilcoxon signed rank test). In 
those with least 12 months post-treatment observation (51/101, 50.5%), median ARR 
declined after initiation of RTX from 1.84 to 0.43 (p<0.001; Wilcoxon signed rank test). 
Finally, in those with at least 12 months observation both pre- and post-RTX treatment 
(34/101, 33.7%), median ARR declined from 1.18 to 0.56 (p=0.002; Wilcoxon signed rank 
test).  
 
Early relapses after starting RTX (n=97) 
Very early relapses after RTX initiation have been described in AQP4-IgG-positive NMOSD 
and may not signify true RTX failure (see discussion). We therefore re-analysed relapse rates 
after excluding relapses occurring within 1 month of RTX. The exact dates of 99/102 (97.1%) 
relapses were known, and 5/99 (5.1%) occurred within 1 month of first RTX infusion. Four 
patients with less than 1 month follow-up on RTX were necessarily excluded from this 
analysis.  With this adjustment, the Poisson regression model showed a 43% (95%CI 26-
57%, p<0.001) reduction in relapse rate. Decline in median ARR was unchanged (table 2). 
 
B-cell depletion (n=121) 
A CD19+ B-cell count <1% of circulating lymphocytes is a commonly used indicator of 
effective B-cell depletion and continued therapeutic action of RTX.30 CD19+ B-cell counts 
were not systematically acquired in all patients, but were available at the time of 57/113 
(50.4%) relapses occurring on RTX. In 12/57 (21.1%) relapses the CD19+ B-cell count was 
≥1%, indicating that the B-cell depleting effect of RTX had waned. However, circulating 
CD19+ B-cells were supressed to <1% in 45/57 (78.9%), indicating disease activity despite 
effective B-cell depletion. Circulating CD19+ B-cells were undetectable at the time of 22/57 
(38.6%) relapses. 
 
The effect of RTX on treatment naïve patients (n=47) versus those with prior exposure to 
non-steroid immunotherapies (n=54) 
To determine if prior exposure to maintenance non-steroid immunotherapies influenced RTX 
treatment effect, we performed a subgroup analysis comparing relapse rates in treatment 
naïve patients (47/101, 46.5%) versus those with previous immunotherapy exposure (54/101, 
53.5%, including 11 patients previously treated with MS-DMTs) (table 1). A greater decline 
in median ARR occurred in treatment naïve patients (p=0.015, Mann Whitney U test). The 
Poisson regression model showed a 63% (95%CI 35-79%, p=0.001) decline in relapse rate in 
this group. The Kaplan-Meier estimate of patients treated 1st line with RTX who are relapse-
free was 79% (95%CI 62-89%) after 1 year and 55% (95%CI 31-73%) after 2 years (figure 
3b). 
 
When RTX was given after other non-steroid immunotherapies, the decline in relapse rate 
was 26% (95%CI 2-44%, p=0.038). After 1 and 2 years, 38% (95%CI 25-52%) and 18% 
(95% CI 7-34%) were relapse-free respectively (figure 3b). We repeated this analysis after 
exclusion of the 11 patients with prior exposure to MS-DMTs and the results were similar 
(table 2), though the observed 25% decline in relapse rate did not reach statistical 
significance (95%CI -3-46%, p=0.077, Poisson regression model). In the 11 patients exposed 
to MS-DMTs, the median ARR declined from 2.19 pre-treatment (median observation period 
49 months) to 1.79 after initiation of RTX (median observation period 13 months). For the 7 
patients with at least 12 months observation pre- and post-RTX treatment, median ARR 
declined from 1.71 to 0.89.   
 
The effect of RTX in adults (n=71) versus children (n=30) 
RTX was initiated before 18 years of age in 30/121 (24.8%), all of whom experienced two or 
more attacks prior to starting RTX. We therefore compared the effect of RTX on relapse rates 
in 30 children versus 71/90 (78.0%) adults, who also had two or more attacks prior to starting 
RTX (table 2). Median duration on RTX was 12.7 months for adults and 11.8 months for 
children, in which 31/71 (43.7%) adults and 17/30 (56.7%) children relapsed. A Poisson 
regression model showed a 42% (95%CI 20-59%, p=0.001) decline in relapse rate for adults 
and a 29% (95%CI -7-53%, p=0.103) decline for children. The proportion of treatment naïve 
patients was 40/71 (56.3%) in the adult group versus 7/30 (23.3%) in the paediatric group. 
CD19+ B-cell counts were available for 22/62 (35.5%) relapses in adults and 30/40 (75.0%) 
relapses in children, and were suppressed to <1% in 19/22 (86.4%) and 21/30 (70.0%) 
respectively.  
 
Use of corticosteroids, steroid-sparing immunotherapies(n=121) 
Maintenance corticosteroid therapy, defined as daily or alternate day dosing of oral 
prednisolone (this excludes short-course intravenous methylprednisolone for acute relapses, 
or single dose pre-medication for RTX infusions), was used in 32/121 (26.4%) of patients 
while receiving RTX treatment, of which 17/121 (14.0%) received continuous treatment, 
7/121 (5.8%) were treated and then tapered to cessation, and 8 (6.6%) restarted maintenance 
corticosteroids following a relapse. Maintenance corticosteroids were not used in 78/121 
(64.5%) and information about steroid use was not available in 11/121 (9.1%).   
 
Continuation or addition of other steroid-sparing immunotherapies with RTX occurred in 
20/121 (16.5%) patients; MMF (8), IVIg (6), AZA (3), methotrexate (2), IVIg with AZA (1). 
One patient received low dose IVIg (0.2mg/kg monthly) for RTX-induced 
hypogammaglobulinaema, and a further patient had recent exposure to alemtuzumab (33 and 
21 months pre-RTX).  We did not analyse these subgroups due to the low number of patients. 
 
Treatment switches (n=121) 
22/121 (18.2%) patients discontinued RTX, due to relapses (16/22, 72.7%) or de-escalation 
of immunotherapy (5/22, 22.7%). These patients commenced a variety of alternative 
immunomodulatory therapies (e.g. MMF [n=4], tocilizumab [n=3], AZA [n=3], IVIg [n=4] 
and other multi-drug regimens). One patient stopped RTX due to an infection (cryptococcal 
meningoencephalitis). 
 
EDSS and visual disability (n=121) 
To determine if EDSS was affected by RTX treatment we compared EDSS at RTX initiation 
and at last review or on switching to an alternative immunotherapy. EDSS data were 
available for 97/121 (80.2%) patients, but scores were not assessed at defined time points 
with respect to relapses. Median (IQR) EDSS score improved from 3.0 (2.0-3.5) at RTX 
initiation to 2.0 (1.0-3.0) at follow-up (z=3.36, p=0.001; Wilcoxon signed rank test).   
 
Visual disability was similarly analysed. VFS scores were calculated on 41/121 (33.9%) 
patients with sufficient data, of whom 21/41 (51.2%) experienced ON during the RTX 
treatment period. Overall, there was no change in median VFS score, which was 2 (1-4) on 
RTX initiation and 2 (0-4) at follow-up (t=1.99, p=0.03; paired t-test). For patients with at 
least one episode of ON during RTX treatment, VFS scores improved in 8/21 (38.1%), 
remained stable in 10/21 (47.6%) and worsened in 3/21 (14.3%).   
 
Tolerance and adverse events  
We did not systematically acquire data on tolerance and adverse events in this study. 
However, the following serious adverse events were reported: anaphylactoid infusion 
reaction (1), hypogammaglobulinaemia (1) and cryptococcal meningoencephalitis (1). No 
patients died during treatment with RTX.  
 
Discussion 
This is the first study to examine RTX efficacy in a large cohort of MOGAD patients. RTX 
treatment led to a 37% decline in relapse rate, and after 2 years of treatment, 33% of patients 
remained relapse-free. This is a less beneficial effect than has been observed with anti-CD20 
B-cell depletion in similar neuroinflammatory disorders – MS and NMOSD. Where 
circulating CD19+ B-cell counts were available, 79% of relapses occurred despite robust B-
cell depletion. The greatest treatment effect (63% decline in relapse rate) was observed in 
patients who received RTX as a first line maintenance immunotherapy. Patients with prior 
exposure to other steroid-sparing medications (usually AZA and MMF), experienced only a 
25% decline in relapses. Separate analyses of adults and children suggested a better response 
in adult patients (42% versus 29% reduction in relapse rates). 
 
The true benefit of RTX in MOGAD may be even less than that observed in this study, when 
one considers the potential influence of regression to the mean. This refers to the tendency of 
a group to return to the average, rather than to sustain an above average relapse rate. To 
assess the quantitative importance of the regression to the mean phenomenon, it is important 
to understand the behaviour of historic cohorts.  For example, in randomised controlled trials 
in relapsing MS, regression to the mean may explain as much as 40% of the reduction of 
relapse rate, which is observed in both treatment and placebo arms.31 In MOGAD, estimates 
of median ARR in untreated and immunosuppressed cohorts have varied greatly and have 
been prejudiced by both testing bias and short observation periods. It is therefore difficult to 
quantify the effect of regression to the mean in studies of treatment effect. However, in this 
study, where the observed treatment effect is relatively small, it is particularly important to 
consider regression to the mean when drawing conclusions.  
 
Previous studies of treatment effect in MOGAD included small numbers of RTX-treated 
patients.  They also observed a reduction of relapse rate following initiation of RTX, but 
described frequent early relapses: A German study reported that 6/9 patients relapsed during 
treatment with RTX.9 An Australasian study included six rituximab-treated patients, of whom 
one patient experienced two relapses despite B-cell depletion.15 Finally, in a European 
paediatric study, 6/9 RTX-treated children relapsed and one child had a severe life-
threatening relapse despite B-cell depletion. Of the three children that did not relapse, two 
were additionally receiving maintenance IVIg.14   
 
It is not clear why RTX appears less effective for MOGAD as compared to MS and NMOSD. 
Phase I and II randomised controlled trials of RTX in relapsing MS met their primary 
endpoints, and the pivotal phase III trials of ocrelizumab, a similar anti-CD20 therapy, versus 
interferon beta-1a, reported a 46-47% lower relapse rate with ocrelizumab, establishing B-
cell depletion as important therapeutic strategy for MS.16-18 Likewise, retrospective studies of 
RTX in NMOSD have consistently reported high response rates with substantial reductions in 
ARR.20-29 The largest meta-analysis of RTX in predominantly AQP4-IgG positive NMOSD 
included 46 studies of 438 patients and calculated a 79% reduction in relapse rate.28 RTX has 
therefore become a dependable maintenance therapy for AQP4-IgG positive NMOSD in 
countries where it is readily available and affordable.          
 
One explanation for apparent lack of efficacy is that this study has selected out a subgroup of 
MOG-IgG positive patients with highly active and treatment-refractory disease. Only 15.1% 
of all MOG-IgG patients that attend the participating centres have been treated with RTX. 
This figure probably over-estimates RTX usage in MOGAD. Firstly, because testing for 
MOG-IgG is not widely available in all countries, and monophasic or infrequently relapsing 
patients are least likely to be tested for MOG-IgG, there is a bias to diagnosing more active 
cases. Secondly, many authors in this study run specialist tertiary or quaternary referral 
clinics and will therefore tend to encounter the more active or treatment-refractory cases. 
High disease activity in this study population is evidenced by the relatively high pre-
treatment median ARR of 1.82, or 1.09 after excluding patients with less than 12 months pre-
treatment observation.  The latter is a more reliable estimate of the true ARR in this group, 
and is nonetheless considerably higher than the median ARR of 0.20-0.38 reported for UK 
and French incident cohorts (patients diagnosed after their index attack).7,8 
 
Selection of increasingly treatment-refractory patients may also explain why treatment naïve 
patients appeared to respond better to RTX than those who had failed treatment with other 
steroid-sparing immunosuppressive medications. Although pre-RTX ARR was higher (2.36 
versus 1.45) in the treatment naïve group, it is doubtful that this accounts fully for the 
improved response observed. A treatment paradox, in which higher relapse rates and poorer 
outcomes are seen in the group receiving more therapy, has been observed in other 
neuroinflammatory disorders and reflects the a priori threshold for initiating such 
treatments.32,33 Similarly, the apparently poor efficacy of RTX observed in retrospective 
systematic reviews of acetylcholine receptor antibody positive myasthaenia gravis (AChR-
MG), has been postulated to result from the inclusion of many ‘burnt out’, treatment-
refractory cases.34,35        
 
We explored whether very early relapses may be accounting for apparently poor efficacy of 
RTX by excluding those occurring within a month of RTX initiation (5% of relapses in this 
study). This increased the calculated decline in relapse rate, but only slightly, from 37% to 
43%. The validity of this adjustment is uncertain in MOGAD, but stems from experience in 
AQP4-IgG-positive NMOSD, where a lag time of 3-4 weeks in terms of relapse-preventing 
effect has been described in several studies, despite achievement of circulating B-cell 
depletion within hours to days of first RTX infusion.24,36 An increased relapse risk during this 
lag time has even been observed by some, possibly due to elevation of systemic B-cell 
activating factor, which could induce antibody secretion by CD20- plasma cells.37,38 For these 
reasons many neurologists treating NMOSD do not consider very early relapses to reflect 
truly RTX-refractory disease.30  
 
Importantly, it may be that circulating CD20+ B-cell depletion with RTX is truly less 
efficacious for MOGAD than for MS and AQP4-IgG-positive NMOSD. Despite their 
overlapping clinical phenotypes, many differences have been identified between the 
immunopathogenic mechanisms underpinning these disorders. It is also unclear, for example 
whether the efficacy of RTX in AQP4-IgG-positive NMOSD is due to suppression of 
antibody production, modulation of downstream antibody-mediated pathways, or a 
combination of mechanisms. Data on longitudinal MOG-IgG titres were not collected as part 
of this study, but may be informative in future studies of treatment effect, as loss of 
seropositivity appears more common in MOGAD as compared to AQP4-IgG-positive 
NMOSD, and seems to correlate (though not completely) with lower relapse risk, at least 
over short-term follow-up.6-9,39,40 It could be that antibody production by CD20- plasma cells, 
or by B-cells sequestered in secondary lymphoid tissue are responsible for RTX-refractory 
MOGAD disease.  
 
Both AQP4-IgG and MOG-IgG are of the IgG1 immunoglobulin subclass, but the evidence 
for a direct pathogenic effect of MOG-IgG in the CNS is less certain than for AQP4-IgG. 
Spadaro et al. (2018) showed that the pathogenicity of human MOG-IgG is dependent on 
interactions with T-cells: In synergy with myelin basic protein-specific T-cells, MOG-IgG 
mediated MS type II pathology, and together with MOG-specific T-cells, it enhanced T-cell 
infiltration.41 Others have shown, using murine models, that MOG-IgG may cause 
complement-mediated demyelination.42,43  
 
It is also interesting that the children in this study experienced only a 29% reduction in 
relapse rates on RTX (which did not reach statistical significance, p=0.103), as compared to 
the 42% decline observed in adults. Children comprised only a quarter of the study 
population, and one of the 30 patients had 9 relapses on RTX, which may have skewed the 
data. A greater proportion of adult patients (56% versus 23%) were treatment naïve prior to 
RTX, which may have affected the observed efficacy, as described above. Finally, of all 
relapses that were known to have occurred in the context of inadequate B-cell depletion 
(CD19+ B-cell count ≥1%), 9/12 (75%) occurred in children.  This could suggest that closer 
monitoring of B-cell counts was warranted in these children, rather than a true failure of B-
cell depletion itself.  Nevertheless, the apparently different response to RTX of adults and 
children with MOGAD merits further study.      
 
Although 45% of the cohort experienced at least one relapse during RTX therapy, only 18% 
of patients switched to an alternative immunotherapy. This could be because on-treatment 
relapses were mild or responded well to acute therapy. The EDSS and VFS data, which show 
a trend towards improving disability and stable visual function, may support this. However, 
these data were incomplete in our study; EDSS and VFS scores were available for 80% and 
35% of the cohort respectively, and were not calculated at designated time points with respect 
to prior attacks. Immunosuppressive therapy is most often commenced or changed in the 
immediate aftermath of an acute relapse, while recovery continues and EDSS has not yet 
stabilised.  The EDSS score is also heavily weighted on motor and ambulatory performance 
and may therefore be poorly sensitive to accrual of visual disability and bladder and bowel 
dysfunction, which are thought to be preferentially affected in MOGAD.7 
 
Another reason for continuing RTX in the face of ongoing relapses may be the limited 
options and evidence base for third-line therapies in MOGAD. A retrospective study that 
compared treatment effects in children with relapsing MOGAD suggested that regular IVIg 
infusions may be the most effective treatment, but this needs further study.14 Other 
monoclonal antibody therapies used for RTX-refractory AQP4-IgG positive NMOSD, such 
as tocilizumab (anti-interleukin-6 receptor), have been used infrequently in MOGAD. 
Finally, reports of severe flares AQP4-IgG positive NMOSD following administration of MS 
disease-modifying therapies, including beta-interferons, fingolimod, natalizumab and 
alemtuzumab, have prompted avoidance of such medications once a diagnosis of antibody-
mediated CNS inflammation is established. In this study, the 11 patients with prior exposure 
to MS therapies did have a relatively high pre-RTX median ARR of 2.19, but we did not 
specifically examine the temporal relationship between relapses and MS therapies. 
 
The limitations of this study include its retrospective design and the necessary inclusion of 
many patients with relatively short on-treatment follow-up periods.  The latter will bias 
analysis of ARRs, often used in this type of study, and this is why we used the Poisson 
regression model as our primary statistical model, to provide a more meaningful analysis of 
treatment effect with such variable follow-up periods. Another limitation is the baseline 
heterogeneity of the cohort in terms of patient ages, MOGAD phenotypes and prior drug 
exposure. Furthermore, many patients received concomitant corticosteroid treatment at 
changing doses, there was no standardised washout from prior steroid-sparing medications 
and a minority of patients continued these treatments alongside RTX therapy. These factors 
influence relapse risk and so introduce a bias to this study, but are inherent to real-world, 
retrospective studies of this nature. The inclusion of all cases improves the generalisability of 
this study and reflects the challenges of managing this rare and unpredictable disorder with 
the potential to cause permanent neurological disability.  Prospective randomised controlled 
trials, in which prior and concomitant drug therapy can be controlled, and where B-cell 
counts and MOG-IgG titres can be systematically acquired, will better define the role of RTX 




An overall decline in MOGAD relapse rates was observed after initiation of RTX. However, 
when compared to similar studies in MS and AQP4-IgG positive NMOSD, RTX appeared 
less effective. Furthermore, many relapses in this study occurred despite robust circulating B-
cell depletion. This study highlights the need to understand the immunopathogenic 
mechanisms underlying MOGAD and the need for prospective head-to-head comparative 
studies of treatment effect, which include longitudinal antibody testing. At present, there is 
enough clinical equipoise to justify randomised placebo-controlled trials in MOGAD, which 







Figure 1: Flow diagram demonstrating data analysis 
 









Table 1: Cohort demographics, clinical phenotypes and previous immunotherapies 
 
 Whole cohort Adults  
 








Patients, n 121 91 30 20 101 
Female, n (%) 71 (58.7) 56 (61.5) 15 (50.0) 14 (70.0) 57 (56.4) 
White, n (%) 103 (85.1) 84 (69.4) 19 (63.3) 19 (95.0) 84 (83.2) 
Median (IQR) onset age, yrs  24.8 (13.1-39.6) 33.0 (22.7-43.5) 7.6 (4.0-9.9) 31.9 (22.5-40.9) 23.2 (10.9-38.8) 
Median (IQR) RTX start age, yrs 29.7 (18.2-44.0) 37.7 (25.5-48.5) 11.7 (8.3-14.0) 32.1 (22.7-41.5) 27.2 (16.4-44.1) 
Disease onset <18years, n (%)  39 (32.2) 9 (9.9) 30 (100) 0  39 (38.6) 
RTX initiation <18years, n (%) 30 (24.7) 0 30 (100) 0  30 (29.7) 
Median (IQR) disease duration 
pre-RTX, mths 
19.1 (5.9-55.0) 12.8 (5.0-49.1) 33.0 (16.3-69.6) 3.3 (1.7-5.1) 26.0 (9.8-70.9) 
Phenotypes, n (%):      
Single attack 20 (16.5) 20 (21.9) 0 20 (100)  
- ON     6 (5.0)     6 (6.6)      6 (30.0)  
- TM     9 (7.4)     9 (9.9)      9 (45.0)  
- ON + TM     5 (4.1)     5 (5.5)      5 (25.0)  
Relapsing 101 (83.5) 71 (78.0) 30 (100)  101 (100) 
- ON     29 (24.0)     27 (29.7)     2 (6.7)      29 (28.7) 
- TM     6 (5.0)     5 (5.5)     1 (3.3)      6 (5.9) 
- ON + TM     29 (24.0)     25 (27.5)     4 (13.3)      29 (28.7) 
- ADEM/ADEM-like     15 12.4)     2 (2.2)     13 (43.3)      15 (14.9) 
- Other / brain    
   involvement 
    22 (18.2)     12 (13.2)     10 (33.3)  
 
    22 (21.8) 
Median pre-RTX ARR 2.25 2.34 1.64  1.82 
No. of steroid-sparing ITs prior 
to RTX, n (%): 
     
- 0 66 (54.5) 59 (64.8) 7 (23.3) 19 (95.0) 47 (46.5) 
- 1  35 (28.9) 19 (20.9) 16 (53.3) 1 (5.0) 34 (33.7) 
- 2 13 (10.7) 9 (9.9) 4 (13.3) 0 13 (12.9) 
- 3+ 7 (5.8) 4 (4.4) 3 (10.0) 0 7 (6.9) 
Types of prior steroid-sparing 
ITs prior to RTX, n (%*) 
     
- None 66 (54.5) 59 (64.8) 7 (23.3) 19 (95.0) 47 (46.5) 
- AZA 27 (22.3) 13 (14.3) 14 (46.7) 1 (5.0) 26 (25.7) 
- MMF 20 (16.5) 14 (15.4) 6 (20.0) 0 20 (19.8) 
- Other IS* 13 (10.7) 9 (9.9) 4 (13.3) 0 13 (12.9) 
- IVIg 7 (5.8) 1 (1.1) 6 (20.0) 0 7 (6.9) 
- Maintenance PLEX 2 (1.7) 1 (1.1) 1 (3.3) 0 2 (2.0) 
- Any MS-DMT 11 (9.1) 8 (8.8) 3 (10.0) 0 11 (10.9) 
- Injectable MS-DMT 9 (7.4) 6 (6.6) 3 (10.0) 0 9 (8.9) 
- Oral/infusible MS-
DMT 
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Figure 3a: Kaplan-Meier plot of relapse-free survival following initiation of rituximab. 
 
Figure 3b: Kaplan-Meier plot of relapse-free survival following initiation of rituximab, 
comparing treatment-naïve patients and those with previous exposure to non-steroid 
immunotherapies 
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